Testing new therapies for pediatric and young adult sarcoma, kidney, and liver cancers
Official title: A Testing Program to Identify Novel Agents for Treatment of Pediatric and AYA High-Risk Sarcoma, Kidney and Liver Cancer
Funded at University of Texas Hlth Science Center · NIH-11538882 · Data updated 2026-11-12
Researchers are testing new drugs and smart combinations in models of pediatric cancers to help guide future treatments for kids and young adults.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | July 1, 2026 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $296,542 |
| NIH project number | 3U01CA263981-05S1 |
| Project ID | NIH-11538882 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are children or young adults with sarcoma, liver cancer, or kidney cancer who may benefit from future pediatric oncology therapies identified through preclinical testing.
✕Less likely to help
Patients not eligible for clinical trials or without access to the specific therapies studied may not directly benefit.
What this research studies
This project continues preclinical work using patient-derived tumor models to identify active drugs and rational combinations for pediatric sarcoma, kidney, and liver cancers. The team analyzes samples and sequencing data to understand how tumors respond and why resistance occurs, aiming to prioritize therapies for clinical testing. The effort builds on prior work and manuscripts, with an emphasis on translational relevance to future patient trials. The 12-month extension will finalize ongoing studies and advance planned testings, molecular characterizations, and dissemination of findings.
Why it matters
Potential benefit: If successful, the work could help identify promising drugs and combinations to move toward clinical testing for pediatric cancers.
How similar studies have gone: Prior preclinical work has yielded identifiably active agents and published results in high-impact journals, supporting continued translational efforts.
Where this research is happening
-
University of Texas Hlth Science Center
San Antonio, United States Active
Researchers
- Principal investigator: Kurmasheva, Raushan — University of Texas Hlth Science Center
- Study coordinator: Kurmasheva, Raushan
Related research
Other NIH-funded projects on the same topics.
-
Finding New Treatments for High-Risk Cancers in Children and Young Adults
This research looks for new medicines and combinations to treat aggressive sarcomas, kidney, and liver cancers in children and young adults.
-
Finding new treatments for high-risk pediatric and young adult cancers.
This study is looking for better treatment options for kids and young adults with tough cancers like sarcoma, kidney cancer, and liver cancer by testing new medicines alongside regular treatments to help those who haven't had success with standard care.
-
AI-powered liver cancer screening using ultrasound blood flow patterns
A new AI-based method analyzes liver blood flow signals to help detect liver cancer early in people with liver disease, especially in settings with limited resources.
-
Aging and liver cancer: new ways to prevent and fight hepatocellular carcinoma
This research explores how aging promotes liver cancer and tests new preventive approaches that could help people at higher risk due to age.
-
Precision 3D Imaging to Monitor Kaposi Sarcoma (KS) with SkinScan3D
A new portable 3D imaging tool called SkinScan3D will help doctors measure KS skin lesions more accurately and quickly, especially in people living with HIV.
-
Precision 3D Imaging to Track Kaposi Sarcoma (KS) with SkinScan3D
A new 3D imaging tool called SkinScan3D helps doctors monitor Kaposi sarcoma lesions more accurately and quickly, especially in settings with high KS burden like East Africa and in U.S. clinics with HIV patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.